Wordt geladen...
Apatinib attenuates phenotypic switching of arterial smooth muscle cells in vascular remodelling by targeting the PDGF Receptor‐β
Apatinib (YN968D1) is a small‐molecule tyrosine kinase inhibitor（TKI）which can inhibit the activity of vascular endothelial growth factor receptor‐2 (VEGFR‐2). It has been reported that apatinib has anti‐tumour effect of inhibiting proliferation and inducing apoptosis of a variety of solid tumour ce...
Bewaard in:
| Gepubliceerd in: | J Cell Mol Med |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7520274/ https://ncbi.nlm.nih.gov/pubmed/32697395 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.15623 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|